ReviewFrontiers in endocrinology2026
Maternal-fetal interface abnormalities in unexplained recurrent pregnancy loss: mechanisms, models, and a framework for subtype identification.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent pregnancy loss (RPL) is a heterogeneous reproductive condition, and unexplained recurrent pregnancy loss (URPL) denotes repeated pregnancy losses for which no established cause is identified after standard evaluation. Recurrent miscarriage (RM) and recurrent spontaneous abortion (RSA) are overlapping terms used in the literature, whereas recurrent implantation failure (RIF) is a related but distinct infertility context. In this Mini Review, URPL is treated as an exclusion-based clinical category rather than a single disease entity. This review examines the hypothesis that a subset of URPL reflects abnormalities in specific cellular and molecular components of the maternal-fetal interface. We focus on maternal compartments, including endometrial epithelial lineage states, decidual stromal dysfunction, and stromal-immune interactions, as well as fetal/trophoblast compartments such as trophoblast lineage defects and broader maternal-fetal interactions, incorporating insights from recent advances in molecular and cellular technologies and human model systems. Particular attention is given to single-cell, spatial, organoid, assembloid, implantation model, trophoblast stem cell, and placental explant studies published from 2024 to 2026. Current data do not establish clinical subtypes for URPL or support treatment selection in routine practice. However, recent molecular and cellular technologies now make it possible to define interface phenotypes with higher resolution and to test whether patient-derived abnormalities are reproducible and perturbable in experimental systems. An interface-centered framework may therefore help move URPL research from broad exclusion-based labels toward experimentally testable subtype identification based on epithelial, decidual, trophoblast, immune, and embryo-endometrial phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.